New hope for Tough-to-Treat myeloma: epunamin combo trial launches
NCT ID NCT07497165
First seen Apr 02, 2026 · Last updated May 08, 2026 · Updated 6 times
Summary
This study tests a new combination of drugs (epunamin plus DECP) in 48 adults with relapsed/refractory multiple myeloma, a blood cancer that has come back or stopped responding to treatment. The goal is to see if this combo can shrink tumors and improve outcomes. Participants must be 18-75 and have had at least one prior treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
ShanxiBethuneH
RECRUITINGTaiyuan, Shanxi, 030000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.